Certara Acquires Specialty CRO Synchrogenix
Certara announced its acquisition of specialty contract research organization Synchrogenix Information Strategies Inc
Certara, a technology-enabled drug development and drug safety consultancy, announced its acquisition of specialty contract research organization (CRO) Synchrogenix Information Strategies Inc. Synchrogenix offers regulatory writing and related services to pharmaceutical, biotechnology and medical device companies worldwide. The acquisition allows Certara to provide preclinical and clinical pharmacology customers with end-to-end drug development consulting and writing services, including preparation of regulatory submissions such BLAs, IND, and NDAs. Synchrogenix has 50 permanent regulatory writers and editors on staff, and has seven offices in North America, Europe, and Asia.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
